Skip to content

Enovis ENOV Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

ESAB logo
ESABESAB
Vericel logo
VericelVCEL
Globus Medical logo
Globus MedicalGMED
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
Avanos Medical logo
Avanos MedicalAVNS
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$589.2M+5.4%
Gross profit$365.5M+10.0%
Operating income$6.5M+114%
Net income-$8.8M+84.3%
EPS (diluted)-$0.15+84.7%

Balance sheet

See full
Cash & equivalents$33.1M-13.9%
Total debt$1.4B-3.1%
Total equity$1.5B-43.6%
Total assets$3.8B-21.4%

Cash flow

See full
Operating cash flow$24.0M+1,601%
CapEx$52.8M+22.1%
Free cash flow-$28.9M+35.7%

Valuation

See full
Market cap$1.23B-40.2%
Enterprise value$2.55B-25.8%
P/S0.5×-0.4×

Profitability

See full
Gross margin60.5%+4.0pp
Operating margin-47%+18.6pp
Net margin-49.9%+24.1pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-55.5%-1,722pp
Debt / equity0.9×+0.4×
Current ratio-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enovis's common stock, shares authorized (in shares)?
Enovis (ENOV) reported common stock, shares authorized (in shares) of $133.33M in Q1 2026.
How has Enovis's common stock, shares authorized (in shares) changed year-over-year?
Enovis's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $133.33M to $133.33M.
What is the long-term trend for Enovis's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Enovis's common stock, shares authorized (in shares) has grown at a -19.7% compound annual growth rate (CAGR), from $400M to $133.33M.